Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- ResearchADCs
- HER1/EGFR
- ResearchMET
- ResearchVEGF
- Role of Genentech BioOncology in VEGF research
- Slide decks and videos
- VEGF and carcinogens
- VEGF in lung cancer
- Prevalence of VEGF
- VEGF and prognosis
- Malignant pleural effusion
- Survival
- Summary
- Evidence of VEGF expression
- VEGF and disease progression
- Importance of interstitial pressure
- Triggers of VEGF production
- Clinical Trials
- Cancer Biomarkers
- Lung Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- VEGF in lung cancer
- Prevalence of VEGF
- VEGF and prognosis
- Malignant pleural effusion
- Survival
- Summary
- Evidence of VEGF expression
- VEGF and disease progression
- Lung Cancer
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Emerging therapeutic options
- Emerging therapeutic options
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- HER Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Emerging therapeutic options
- Emerging therapeutic options
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Non-Antibody Biologics
- Apoptosis
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Multiple Myeloma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- B-cell Surface Proteins
- HER Signaling
- Parsatuzumab (Anti-EGFL7)
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Emerging therapeutic options
- Emerging therapeutic options
- Glossary
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Antibody-Drug conjugates
Lung Cancer
Disease Information
Genentech BioOncology is dedicated to advancing the science of lung cancer therapy through comprehensive research and education. Lung cancers typically arise from epithelial linings of air passages.1 The presence of lung tumors may be confirmed from a variety of sources, including the sputum, pleural fluid, or other lung samples.2 Depending upon the cellular morphology under a microscope, lung cancer is broadly divided into 2 main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).2
Types of Lung Cancer
- SCLC: Approximately 13% of lung cancers belong to the SCLC category. This type of lung cancer is a more aggressive form of the disease and tends to spread quickly2
- NSCLC: A vast majority of lung cancers (≈87%) belong to the NSCLC category.2 Based on histologic features, NSCLC is further divided into 3 main subtypes, namely adenocarcinoma, squamous cell carcinoma, and large cell carcinoma2
- Squamous cell carcinomas typically arise from thin, flat squamous cells; in contrast, adenocarcinomas arise from mucus-secreting cells that line the alveoli1
Lung Cancer Demographic Statistics
- Lung cancer is the second most common cancer in both men (second only to prostate cancer) and women (second only to breast cancer), accounting for ≈15% of all new cancers diagnosed1
- Lung cancer mainly afflicts older people, with a reported average age of 71 years at the time of diagnosis; fewer than 3% of lung cancers are detected in people younger than 45 years1
- The American Cancer Society estimates that in 2010, 222,520 new cases of lung cancer were diagnosed in the United States (116,750 men and 105,770 women).1 Studies indicate that African American men are ≈40% more likely to develop lung cancer than Caucasian men1
- More people succumb to lung cancer than to colon, breast, and prostate cancers combined.1 Current estimates indicate that more than 400,000 lung cancer survivors live in the United States today1
- The American Cancer Society estimates 157,300 lung cancer deaths to occur annually (86,220 men and 71,080 women), accounting for ≈28% of all cancer deaths1,3
Lung Cancer Epidemiology
Several risk factors have been identified that make people more susceptible to lung cancer1:
- Smoking is a leading risk factor for lung cancer, accounting for ≈87% of lung cancer deaths1
- Second-hand smoke also remains a major cause for concern, accounting for ≈3,000 lung cancer deaths each year1
- People who quit smoking before they reach age 50 reduce their risk of dying from lung cancer by half in the next 15 years, compared with those who continue to smoke1
- Additional risk factors for lung cancer include exposure to asbestos fibers, diesel exhaust, radiation, and high levels of arsenic in the drinking water1
Other links to lung cancer disease information
These links give a sampling of other sites offering information on lung cancer, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Lung Cancer
- ASCO Cancer Portals - Lung Cancer
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- American Cancer Society. Lung cancer. www.cancer.org/acs/groups/cid/
documents/webcontent/003115-pdf.pdf. Accessed April 14, 2011. - 2.
- US Department of Health and Human Services. National Cancer Institute. What you need to know about™ lung cancer. www.cancer.gov/cancertopics/wyntk/lung/wyntk_lung.pdf. Accessed April 14, 2011.
- 3.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed April 14, 2011.